Find Clinical Trial

Phase I dose-escalation study of oral administration of Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in patients with solid tumour

← Back
Study Phase

Phase 1

Therapeutic Area


Active substance/
Medical device


SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS078454
Protocol CodeCL1-78454-002
EudraCT Code2009-013692-22

Documents and links

Results summary READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.